Yangyin Yiqi Mixture Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats through Inhibiting TGF-1/Smad Pathway and Epithelial to Mesenchymal Transition

被引:16
|
作者
Meng, Lihong [1 ]
Zhang, Xiaomei [2 ]
Wang, Hong [3 ,4 ]
Dong, Huan [1 ]
Gu, Xiaofeng [1 ]
Yu, Xiaolin [1 ]
Liu, Yushan [1 ]
机构
[1] Beijing Univ Chinese Med, 11 North 3rd Ring Rd, Beijing 100029, Peoples R China
[2] Beijing Univ Chinese Med, Dongfang Hosp, Dept Resp Med, 6 1st Dist Fangxingyuan, Beijing 100078, Peoples R China
[3] Shunyi Hosp, Beijing Chinese Med Hosp, 5 Zhanqian East St, Beijing 101300, Peoples R China
[4] Capital Med Univ, Beijing Chinese Med Hosp, Art Museum, 23 Houjie St, Beijing 100010, Peoples R China
关键词
MYOFIBROBLAST; ACTIVATION; MECHANISMS; RECEPTOR;
D O I
10.1155/2019/2710509
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective. The aim of the current study was to investigate the protective effect of Yangyin Yiqi Mixture (YYYQ) on Bleomycin-induced pulmonary fibrosis in rats based on TGF-1/Smad signal pathway and epithelial to mesenchymal transition (EMT). Methods. 120 Wistar rats were randomly divided into six groups: control group, BLM group, BLM + Pred group, BLM+YYYQ-L group, BLM+YYYQ-M group, and BLM+YYYQ-H group. Rats were given an intratracheal instillation of 3 mg/kg BLM to establish the pulmonary fibrosis model and followed by different dosages of YYYQ (11, 22, 44g/kg, via intragastric gavage) or prednisone soluble (4.2mg/kg, via intragastric gavage) or water. After 14 days and 28 days, tissue sections were stained with hematoxylin-eosin and Masson's trichrome to observe histopathological changes. Protein levels of TGF-1, CTGF, Interleukin 18, and hydroxyproline were detected by ELISA method, and mRNA expressions of TGF-1, TRI, TRII, Smad3, Smad7, -SMA, E-cadherin, laminin, and collagen I were detected by RT-PCR. Results. TGF-1, CTGF, Interleukin 18, and hydroxyproline levels and mRNA expression of TGF-1, TRI, TRII, Smad3, -SMA, laminin, and collagen I were significantly increased (p <0.01), while Smad7 and E-cadherin levels were significantly decreased in BLM group (p <0.01). YYYQ-M and YYYQ-H group had downregulated the TGF-1, CTGF, hydroxyproline contents, and mRNA expression of TGF-1, TRI, TRII, Smad3, -SMA, laminin, and collagen I and upregulated mRNA levels of Smad7 and E-cadherin significantly (p <0.01 or p <0.05). The result from the present study, which was also supported by histological evidence, suggested that YYYQ-M group and YYYQ-H group exhibited better treatment effect on Bleomycin-induced pulmonary fibrotic rats when compared to that of BLM + Pred group (p <0.01). Meanwhile, the effect of YYYQ, in three different dosages, on the level of interleukin 18 was not significant. Conclusion. These results showed that YYYQ has the potential of ameliorating the progression of pulmonary fibrosis, and the mechanism may be related to suppressing TGF-1/Smad signal pathway and EMT in BLM-induced pulmonary fibrosis of rats.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Vincamine Ameliorates Epithelial-Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis in Rats; Targeting TGF-β/MAPK/Snai1 Pathway
    Alaaeldin, Rania
    Mohyeldin, Reham H.
    Bekhit, Amany Abdlrehim
    Gomaa, Wafaey
    Zhao, Qing-Li
    Fathy, Moustafa
    MOLECULES, 2023, 28 (12):
  • [2] Emodin ameliorates bleomycin-induced pulmonary fibrosis in rats by suppressing epithelial-mesenchymal transition and fibroblast activation
    Guan, Ruijuan
    Wang, Xia
    Zhao, Xiaomei
    Song, Nana
    Zhu, Jimin
    Wang, Jijiang
    Wang, Jin
    Xia, Chunmei
    Chen, Yonghua
    Zhu, Danian
    Shen, Linlin
    SCIENTIFIC REPORTS, 2016, 6
  • [3] Polydatin prevents bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β/Smad/ERK signaling pathway
    Liu, Yan-Lu
    Chen, Bao-Yi
    Nie, Juan
    Zhao, Guang-Hui
    Zhuo, Jian-Yi
    Yuan, Jie
    Li, Yu-Cui
    Wang, Ling-Li
    Chen, Zhi-Wei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (05)
  • [4] Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition
    Han, Qian
    Lin, Lianjun
    Zhao, Beilei
    Wang, Nanping
    Liu, Xinmin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 500 (04) : 839 - 845
  • [5] Polydatin ameliorates pulmonary fibrosis by suppressing inflammation and the epithelial mesenchymal transition via inhibiting the TGF-/Smad signaling pathway
    Qiu, Yue
    Pan, Xue
    Hu, Yahui
    RSC ADVANCES, 2019, 9 (14) : 8104 - 8112
  • [6] Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-β1/Smad-Mediated Epithelial to Mesenchymal Transition
    Zhou, Yan
    He, Zhong
    Gao, Yuan
    Zheng, Rui
    Zhang, Xiaoye
    Zhao, Li
    Tan, Mingqi
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [7] Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF- β 1 signaling pathway
    Li, Shimeng
    Liu, Zhichao
    Jiao, Xiaodan
    Gu, Jinying
    Liu, Zhigang
    Meng, Lingxin
    Li, Wenqi
    Zhang, Tiantian
    Liu, Jing
    Chai, Dan
    Liu, Jiaai
    Yang, Zhongyi
    Liu, Yuming
    Jiao, Ran
    Li, Xiaohe
    Zhou, Honggang
    Zhang, Yanping
    BIOCHEMICAL PHARMACOLOGY, 2024, 225
  • [8] Geniposide ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β/Smad and p38MAPK signaling pathways
    Yin, Jian-Bin
    Wang, Ying-Xia
    Fan, Su-Su
    Shang, Wen-Bin
    Zhu, Yu-Shan
    Peng, Xue-Rong
    Zou, Cheng
    Zhang, Xuan
    PLOS ONE, 2024, 19 (09):
  • [9] Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway
    Chen, Shanshan
    Wei, Yuli
    Li, Shimeng
    Miao, Yang
    Gu, Jinying
    Cui, Yunyao
    Liu, Zhichao
    Liang, Jingjing
    Wei, Luqing
    Li, Xiaohe
    Zhou, Honggang
    Yang, Cheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [10] Licoricesaponin G2 ameliorates bleomycin-induced pulmonary fibrosis via targeting TNF-α signaling pathway and inhibiting the epithelial-mesenchymal transition
    Ma, Jing
    Ding, Lu
    Zang, Xiaoyu
    Wei, Ruonan
    Yang, Yingying
    Zhang, Wei
    Su, Hang
    Li, Xueyan
    Li, Min
    Sun, Jun
    Zhang, Zepeng
    Wang, Zeyu
    Zhao, Daqing
    Li, Xiangyan
    Zhao, Linhua
    Tong, Xiaolin
    FRONTIERS IN PHARMACOLOGY, 2024, 15